Roles of Central Catecholamine and Hypothalamic Neuropeptide Y Genome in the Development of Tolerance to Phenylpropanolamine-Mediated Appetite Suppression

Behavioral Neuroscience

Volumn 121, Issue 5, 2007, Pages 933-940

  Hsieh, Yih Shou ^a   Yang, Shun Fa ^a   Chiou, Hui Ling ^a   Kuo, Dong Yih ^a  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

brain; catecholamine; feeding behavior; NPY; phenylpropanolamine

Indexed keywords

AMFEBUTAMONE; ANTISENSE OLIGODEOXYNUCLEOTIDE; CATECHOLAMINE; COMPLEMENTARY DNA; MESSENGER RNA; METIROSINE; NEUROPEPTIDE Y; PHENYLPROPANOLAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANOREXIA; APPETITE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG DOSE INCREASE; FEEDING BEHAVIOR; GENOME; HYPOTHALAMUS; MALE; NONHUMAN; RAT; REPEATED DRUG DOSE; TREATMENT OUTCOME; WEIGHT REDUCTION;

AMPHETAMINE; ANIMALS; APPETITE DEPRESSANTS; BODY WEIGHT; BUPROPION; CATECHOLAMINES; CATHETERIZATION; CENTRAL NERVOUS SYSTEM; DOPAMINE UPTAKE INHIBITORS; DRUG TOLERANCE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEEDING BEHAVIOR; HYPOTHALAMUS; INJECTIONS, INTRAVENTRICULAR; MALE; NEUROPEPTIDE Y; OLIGONUCLEOTIDES, ANTISENSE; PHENYLPROPANOLAMINE; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SYNAPTIC TRANSMISSION; TYROSINE 3-MONOOXYGENASE;

EID: 35748976285     PISSN: 07357044     EISSN: None     Source Type: Journal    
DOI: 10.1037/0735-7044.121.5.933     Document Type: Article

References (55)

1. Argyelan M., Szabo Z., Kanyo B., Tanacs A., Kovacs Z., Janka Z., and Pavics L. Dopamine transporter availability in medication free and in bupropion treated depression: A 99mTc-TRODAT-1 SPECT study. Journal of Affective Disorders 89 (2005) 115-123
2. Arsenijevic D., de Bilbao F., Plamondon J., Paradis E., Vallet P., Richard D., et al. Increased infarct size and lack of hyperphagic response after focal cerebral ischemia in peroxisome proliferator-activated receptor beta-deficient mice. Journal of Cerebral Blood Flow and Metabolism 26 (2006) 433-445
3. Bi S., Robinson B.M., and Moran T.H. Acute food deprivation and chronic food restriction differentially affect hypothalamic NPY mRNA expression. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 285 (2003) R1030-R1036
4. Billes S.K., and Cowley M.A. Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice [Electronic version]. Neuropsychopharmacology 32 (2007) 822-834
5. Billington C.J., Briggs J.E., Harker S., Grace M., and Levine A.S. Neuropeptide Y in hypothalamic paraventricular nucleus: A center coordinating energy metabolism. American Journal of Physiology 266 (1994) R1765-R1770
6. Borovicka M.C., Fuller M.A., Konicki P.E., White J.C., Steele V.M., and Jaskiw G.E. Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. Journal of Clinical Psychiatry 63 (2002) 345-348
7. Borrelli B., Spring B., Niaura R., Kristeller J., Ockene J.K., and Keuthen N.J. Weight suppression and weight rebound in ex-smokers treated with fluoxetine. Journal of Consulting and Clinical Psychology 67 (1999) 124-131
8. Cannon C.M., Abdallah L., Tecott L.H., During M.J., and Palmiter R.D. Dysregulation of striatal dopamine signaling by amphetamine inhibits feeding by hungry mice. Neuron 44 (2004) 509-520
9. Cheng J.T., and Kuo D.Y. Both α1-adrenergic and D1-dopaminergic neurotransmissions are involved in phenylpropanolamine-mediated feeding suppression in mice. Neuroscience Letters 347 (2003) 136-138
10. Chomczynski P., and Sacchi N. Single-step method of RNA isolation by acid quanidinium thiocyanate-phenol-chloroform extraction. Analytical Biochemistry 162 (1987) 156-159
11. Chronwall B.M., DiMaggio D.A., Massari V.J., Pickel V.M., Ruggiero D.A., and O'Donohue T.L. The anatomy of neuropeptide-Y-containing neurons in rat brain. Neuroscience 15 (1985) 1159-1181
12. Coelho E.F., Ferrari M.F., Maximino J.R., and Fior-Chadi D.R. Change in the expression of NPY receptor subtypes Y1 and Y2 in central and peripheral neurons related to the control of blood pressure in rats following experimental hypertension. Neuropeptides 38 (2004) 77-82
13. Cooper T.V., Klesges R.C., Debon M.W., Zbikowski S.M., Johnson K.C., and Clemens L.H. A placebo controlled randomized trial of the effects of phenylpropanolamine and nicotine gum on cessation rates and postcessation weight gain in women. Addictive Behaviors 30 (2005) 61-75
14. Delorio N.M. Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication. Journal of Emergency Medicine 26 (2004) 305-307
15. De Quidt M.E., and Emson P.C. Distribution of neuropeptide Y-like immunoreactivity in the rat central nervous system-II. Immunohistochemical analysis. Neuroscience 18 (1986) 545-618
16. Gillard E.R., Dang D.Q., and Stanley B.G. Evidence that neuropeptide Y and dopamine in the perifornical hypothalamus interact antagonistically in the control of food intake. Brain Research 628 (1993) 128-136
17. Hays J.T., Hurt R.D., Rigotti N.A., Niaura R., Gonzales D., Durcan M.J., et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. A randomized, controlled trial. Annals of Internal Medicine 135 (2001) 423-433
18. Hsieh Y.S., Hsu J.D., Yang S.F., and Kuo D.Y. Immunohistochemical and genomic evidence for the involvement of hypothalamic neuropeptide Y in phenylpropanolamine-mediated appetite suppression. Peptides 25 (2004) 2155-2161
19. Hulsey M.G., Pless C.M., White B.D., and Martin R.J. ICV administration of anti-NPY antisense oligonucleotide: Effects on feeding behavior, body weight, peptide content and peptide release. Regulatory Peptides 59 (1995) 207-214
20. Jeanrenaud B., and Rohner-Jeanrenaud F. Effects of neuropeptides and leptin on nutrient partitioning: Dysregulations in obesity. Annual Review of Medicine 52 (2001) 339-351
21. Kalra S.P., and Kalra P.S. NPY and cohorts in regulating appetite, obesity and metabolic syndrome: Beneficial effects of gene therapy. Neuropeptides 38 (2004) 201-211
22. Klesges R.C., Klesges L.M., DeBon M., Shelton M.L., Isbell T.R., and Klem M.L. Effects of phenylpropanolamine on withdrawal symptoms. Psychopharmacology 119 (1995) 85-91
23. Klesges R.C., Klesges L.M., Meyers A.W., Klem M.L., and Isbell T. The effects of phenylpropanolamine on dietary intake, physical activity, and body weight after smoking cessation. Clinical Pharmacology and Therapeutics 47 (1990) 747-754
24. Klimek V., Nowak G., and Czyrak A. Central effects of repeated treatment with bupropion. Polish Journal of Pharmacology & Pharmacy 37 (1985) 243-252
25. Kokare D.M., Dandekar M.P., Chopde C.T., and Subhedar N. Interaction between neuropeptide Y and alpha-melanocyte stimulating hormone in amygdala regulates anxiety in rats. Brain Research 1043 (2005) 107-114
26. Kroner S., Rosenkranz J.A., Grace A.A., and Barrionuevo G. Dopamine modulates excitability of basolateral amygdala neurons in vitro. Journal of Neurophysiology 93 (2005) 1598-1610
27. Kuo D.Y. Further evidence for the mediation of both subtypes of dopamine D1/D2 receptors and cerebral neuropeptide Y (NPY) in amphetamine-induced appetite suppression. Behavioural Brain Research 147 (2003) 149-155
28. Kuo D.Y., and Cheng J.T. Role of cerebral dopamine but not plasma insulin, leptin and glucocorticoid in the development of tolerance to the anorectic effect of amphetamine. Neuroscience Research 44 (2002) 63-69
29. Kuo D.Y., Hsu C.T., and Cheng J.T. Role of hypothalamic neuropeptide Y (NPY) in the change of feeding behavior induced by repeated treatment of amphetamine. Life Sciences 70 (2001) 243-251
30. Kuo D.Y., Inui A., and Cheng J.T. Effect of repeated treatment of amphetamine on the change of feeding response in NPY overexpressing mice. Neuroscience Letters 329 (2002) 359-361
31. Lee F., Stafford I., and Hoebel B.G. Similarities between the stimulus properties of phenylpropanolamine and amphetamine. Psychopharmacology 97 (1989) 410-412
32. Leibowitz S.F., and Rossakis C. Pharmacological characterization of perifornical hypothalamic dopamine receptors mediating feeding suppression in the rats. Brain Research 172 (1979) 115-130
33. Lewis D.E., Shellard L., Koeslag D.G., Boer D.E., and Williams G. Intense exercise and food restriction cause similar hypothalamic neuropeptide Y increases in rats. American Journal of Physiology 264 (1993) E279-E284
34. Li L., Jonsson-Rylander A.C., Abe K., and Zukowska Z. Chronic stress induces rapid occlusion of angioplasty-injured rat carotid artery by activating neuropeptide Y and its Y1 receptors. Arteriosclerosis, Thrombosis, and Vascular Biology 25 (2005) 2075-2080
35. Ma S., and Morilak D.A. Norepinephrine release in medial amygdala facilitates activation of the hypothalamic-pituitary-adrenal axis in response to acute immobilisation stress. Journal of Neuroendocrinology 17 (2005) 22-28
36. Mersfelder T.L. Phenylpropanolamine and stroke: The study, the FDA ruling, the implications [Review]. Cleveland Clinic Journal of Medicine 68 (2001) 208-209 213-219, 223
37. Morris B.J. Neuronal localization of neuropeptide Y gene expression in rat brain. Journal of Comparative Neurology 290 (1989) 358-368
38. Morris M.J., Tortelli C.F., Hart D.P., and Delbridge L.M. Vascular and brain neuropeptide Y in banded and spontaneously hypertensive rats. Peptides 25 (2004) 1313-1319
39. Moya-Huff F., and Maher T.J. Adrenergic receptor subtype activation by (+)-, (-)- and (±)-norephedrine in the pithed rat. Journal of Pharmacy and Pharmacology 39 (1987) 108-112
40. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates. 2nd ed. (1986), Academic Press, Sydney, Australia
41. Rauhut A.S., Neugebauer N., Dwoskin L.P., and Bardo M.T. Effect of bupropion on nicotine self-administration in rats. Psychopharmacology (Berlin) 169 (2003) 1-9
42. Ritter R.C., Slusser P.G., and Stone S. Glucoreceptors controlling feeding and blood glucose: Location in the hindbrain. Science 213 (1981, July 24) 451-452
43. Schank J.R., Ventura R., Puglisi-Allegra S., Alcaro A., Cole C.D., Liles L.C., et al. Dopamine beta-hydroxylase knockout mice have alterations in dopamine signaling and are hypersensitive to cocaine. Neuropsychopharmacology 31 (2006) 2221-2230
44. Schteingart D.E. Effectiveness of phenylpropanolamine in the management of moderate obesity. International Journal of Obesity 16 (1992) 487-493
45. Sorensen G., Lindberg C., Wortwein G., Bolwig T.G., and Woldbye D.P. Differential roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation. Journal of Neuroscience Research 77 (2004) 723-729
46. Svec F., Muehlenhein M., and Porter J. The effects of phenylpropanolamine on Zucker rats selected for fat food preference. Nutritional Neuroscience 6 (2003) 93-102
47. Velkoska E., Cole T.J., and Morris M.J. Early dietary intervention: Long-term effects on blood pressure, brain neuropeptide Y, and adiposity markers. American Journal of Physiology-Endocrinology and Metabolism 288 (2005) E1236-E1243
48. Wellman P.J., and Davies B.T. Reversal of cirazoline- and phenylpropanolamine-induced anorexia by the α1-adrenergic receptor antagonist prazosin. Pharmacology, Biochemistry and Behavior 42 (1992) 97-100
49. Wellman P.J., and Sellers T.L. Weight loss induced by chronic phenylpropanolamine: Anorexia and brown adipose tissue thermogenesis. Pharmacology, Biochemistry and Behavior 24 (1986) 605-611
50. Winders S.E., Amos J.C., Wilson M.R., Rushing P.A., Dykstra T., and Coday M.C. Effects of chronic phenylpropanolamine infusion and termination of body weight, food consumption and water consumption in rats. Psychopharmacology 114 (1994) 513-519
51. Woods S.C., Seeley R.J., Porte J.D., and Schwartz M.W. Signals that regulate food intake and energy homeostasis. Science 280 (1998, May 29) 1378-1382
52. Yoshihiro T., Honma S., Mitome M., and Honma K.I. Methamphetamine stimulates the release of neuropeptide Y and noradrenaline from the paraventricular nucleus in rats. Brain Research 707 (1996) 119-121
53. Yuan J., Callahan B.T., McCann U.D., and Ricaurte G.A. Evidence against an essential role of endogenous brain dopamine in methamphetamine-induced dopaminergic neurotoxicity. Journal of Neurochemistry 77 (2001) 1338-1347
54. Zarrindast M.R., and Hosseini-Nia T. Anorectic and behavioural effects of bupropion. General Pharmacology 19 (1988) 201-204
55. Zukowska Z., Pons J., Lee E.W., and Li L. Neuropeptide Y: A new mediator linking sympathetic nerves, blood vessels and immune system?. Canadian Journal of Physiology and Pharmacology 81 (2003) 89-94